CD4⁺ T cell response to SARS-CoV-2. a, Representative Elispot assays for the production on IFN-γ in whole and CD8⁻ PBMCs isolated from HCW-PI, plated at 2 × 10⁵ cells per well and incubated with mixes of 15 aa peptides (overlapping by 11 aa) from SARS-CoV-2 S1, S2, M and N proteins, control (Ctrl) HLA-I and HLA-II epitope mixes and DMSO solvent (Neg). b, Summary of Elispot assays for the production of IFN-γ in whole versus CD8⁻ PBMCs using n = 10 HCW-PI incubated with peptide mixes as in a. Results are shown as mean SFC per 10⁶ PBMCs. Significance was determined by two-sided Wilcoxon test, *P

Citation: Immune T cell defense is coping with COVID-19 variants of concern (for now) (2022, December 1) retrieved 21 December 2023 from https://medicalxpress.com/news/2022-12-immune-cell-defense-coping-covid-.html